Ipsen Acquires Kartos Therapeutics for Up to $1.75 Billion

Ipsen entered into a definitive merger agreement to acquire clinical-stage biopharmaceutical company Kartos Therapeutics. The deal brings navtemadlin, an oral MDM2 inhibitor in Phase III for TP53 wild-type myelofibrosis, into Ipsen’s late-stage oncology pipeline, with $450 million paid upfront and up to $1.3 billion in regulatory and sales-related milestones.